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Background: Confirming complete neointimal coverage after implantation of drug-eluting stents (DES) is clinically important because incomplete 
stent coverage is responsible for late stent thrombosis and sudden cardiac death. Approximately 200,000.00 patients who receive stents annually 
undergo a non-cardiac surgical procedure less than 12 months after stent placement and require dual antiplatelet therapy (DAPT) discontinuation. 
Cancer is a hypercoagulable state and increases stent thrombosis risk seven fold. This study used optical coherence tomography (OCT) to guide 
antiplatelet therapy in the perioperative period in cancer patients.
methods: Diagnostic left heart catheterization and OCT were performed on 14 symptomatic cancer patients referred for precancer therapy 
risk stratification. All lesions with DES placed within the prior 1 to 12 months were evaluated for endothelialization, apposition, and neointimal 
hyperplasia throughout each stent. A cutoff of <10% malapposition and >90% endothelialization was used for discontinuation of the second 
antiplatelet agent after consultation with the referring Oncologist. All patients continued aspirin throughout cancer therapy and were followed for up 
to 18 months after their procedure.
results: A total of 4355 struts were analyzed in 29 stents across 21 separate lesions. Endothelial strut coverage, luminal cross-sectional 
area (CSA), and stent CSA were measured on 451 individual OCT frames. Based on our analysis, 13 patients (93%) were sent for a non-cardiac 
surgery without further percutaneous coronary intervention (PCI). One patient (7%) required repeat PCI to appose a previously malapposed and 
unendothelialized stent. All procedures were performed with patients on aspirin and off a second antiplatelet agent. No major adverse cardiovascular 
events occurred in the post-operative period; one patient died of sepsis.
conclusion: OCT can be used to safely discontinue the second antiplatelet agent prior to cancer therapy in a patient population with CAD and 
recent PCI.
